MedTrace Logo

Study of Perioperative NP137 and FOLFIRINOX in Resectable Pancreatic Cancer

NCT06203821 · Status: NOT_YET_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 25

Last updated 2026-02-05

No results posted yet for this study

Summary

The objective of this study is to investigate whether adding the study drug, NP137, to a patient's treatment regimen (before surgery and in combination with chemotherapy afterward) can alter the behavior of pancreatic cancer..

Conditions

Interventions

DRUG

NP137

NP137 for the Treatment of Resectable Pancreatic Cancer

Sponsors & Collaborators

  • NETRIS Pharma

    collaborator INDUSTRY

  • Aram Hezel

    lead OTHER

Principal Investigators

  • Aram Hezel · University of Rochester

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-09-01
Primary Completion
2027-05-30
Completion
2032-09-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06203821 on ClinicalTrials.gov